{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=medical+therapy&page=26",
    "query": {
      "intervention": "medical therapy",
      "page": 26
    },
    "page_size": 10
  },
  "pagination": {
    "page": 26,
    "page_size": 10,
    "total_count": 4416,
    "total_pages": 442,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=medical+therapy&page=27&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=medical+therapy&page=25&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-16T19:49:56.780Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07254884",
      "title": "Safety and Efficacy of 2910 nm Fiber Laser Resurfacing and Laser-Coring",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Rhytids",
        "Skin Laxity"
      ],
      "interventions": [
        {
          "name": "2,910 nm mid-infrared erbium-doped fluoride fiber glass laser (UltraClear, Acclaro Medical)",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "FA Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "45 Years to 85 Years"
      },
      "enrollment_count": 40,
      "start_date": "2025-11-24",
      "completion_date": "2026-11",
      "has_results": false,
      "last_update_posted_date": "2026-09-01",
      "last_synced_at": "2026-10-16T19:49:56.780Z",
      "location_count": 1,
      "location_summary": "Edina, Minnesota",
      "locations": [
        {
          "city": "Edina",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07254884"
    },
    {
      "nct_id": "NCT06865885",
      "title": "LDL-C Optimization Using Inclisiran in Patients in Which Drug-Drug Interactions Limit LDL Lowering",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Drug Interactions",
        "Primary Prevention",
        "Cardiometabolic Syndrome",
        "LDL-Cholersterol Lowering"
      ],
      "interventions": [
        {
          "name": "Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Diego",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 100,
      "start_date": "2025-04-02",
      "completion_date": "2027-03-31",
      "has_results": false,
      "last_update_posted_date": "2026-07-13",
      "last_synced_at": "2026-10-16T19:49:56.780Z",
      "location_count": 1,
      "location_summary": "La Jolla, California",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06865885"
    },
    {
      "nct_id": "NCT00917384",
      "title": "Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and Adenocarcinoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Gastric Cancer",
        "Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "ramucirumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Best Supportive Care (BSC)",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 355,
      "start_date": "2009-08",
      "completion_date": "2015-12",
      "has_results": true,
      "last_update_posted_date": "2019-09-25",
      "last_synced_at": "2026-10-16T19:49:56.780Z",
      "location_count": 14,
      "location_summary": "Bakersfield, California • La Jolla, California • Redlands, California + 11 more",
      "locations": [
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Redlands",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00917384"
    },
    {
      "nct_id": "NCT03732352",
      "title": "18F-FDG PET and Osimertinib in Evaluating Glucose Utilization in Patients with EGFR Activated Recurrent Glioblastoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "EGFR Gene Amplification",
        "EGFR Gene Mutation",
        "Glioblastoma",
        "Recurrent Glioblastoma",
        "Supratentorial Glioblastoma",
        "TP53 Wt Allele"
      ],
      "interventions": [
        {
          "name": "Fludeoxyglucose F-18",
          "type": "OTHER"
        },
        {
          "name": "Osimertinib",
          "type": "DRUG"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Jonsson Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2018-11-28",
      "completion_date": "2024-01-31",
      "has_results": false,
      "last_update_posted_date": "2024-11-12",
      "last_synced_at": "2026-10-16T19:49:56.780Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03732352"
    },
    {
      "nct_id": "NCT06834126",
      "title": "Papaverine in Combination With Radiation Therapy for the Treatment of Locally Advanced Rectal Cancer, DINOMITE Trial",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Locally Advanced Rectal Adenocarcinoma",
        "Stage II Rectal Cancer AJCC v8",
        "Stage III Rectal Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Consolidation Therapy",
          "type": "DRUG"
        },
        {
          "name": "Functional Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Gastrointestinal Endoscopy",
          "type": "PROCEDURE"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Papaverine",
          "type": "DRUG"
        },
        {
          "name": "Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Total Mesorectal Excision",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "City of Hope Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 36,
      "start_date": "2025-04-07",
      "completion_date": "2028-09-19",
      "has_results": false,
      "last_update_posted_date": "2026-07-22",
      "last_synced_at": "2026-10-16T19:49:56.780Z",
      "location_count": 1,
      "location_summary": "Duarte, California",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06834126"
    },
    {
      "nct_id": "NCT06004674",
      "title": "Using Placental Pathology to Prevent Recurrent Adverse Pregnancy Outcomes: A Pilot Project",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Adverse Pregnancy Outcome"
      ],
      "interventions": [
        {
          "name": "Lovenox 40mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Endeavor Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 20,
      "start_date": "2023-12-26",
      "completion_date": "2027-03",
      "has_results": false,
      "last_update_posted_date": "2026-07-23",
      "last_synced_at": "2026-10-16T19:49:56.780Z",
      "location_count": 1,
      "location_summary": "Evanston, Illinois",
      "locations": [
        {
          "city": "Evanston",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06004674"
    },
    {
      "nct_id": "NCT05284513",
      "title": "Collaborative Approach to Reach Everyone With Familial Hypercholesterolemia (CARE-FH)",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Familial Hypercholesterolemia"
      ],
      "interventions": [
        {
          "name": "FH diagnosis program",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Implementation strategy package: Develop and implement tools for quality monitoring",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Implementation strategy package: Develop educational materials",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Implementation strategy package: Conduct educational outreach visits",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Implementation strategy package: Intervene with clinicians and patients to enhance",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Behavioral (e.g., Psychotherapy, Lifestyle Counseling) Implementation strategy package: Identify and prepare champions Clinical lipid champions",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Implementation strategy package: Audit and provide feedback",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Implementation strategy package: Stage implementation scale up",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Geisinger Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "26 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "26 Years and older"
      },
      "enrollment_count": 532,
      "start_date": "2022-09-09",
      "completion_date": "2027-01",
      "has_results": false,
      "last_update_posted_date": "2025-12-22",
      "last_synced_at": "2026-10-16T19:49:56.780Z",
      "location_count": 1,
      "location_summary": "Multiple Locations, Pennsylvania",
      "locations": [
        {
          "city": "Multiple Locations",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05284513"
    },
    {
      "nct_id": "NCT03547206",
      "title": "Efficacy & Safety of RPh201 Treatment in Patients With Previous Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Nonarteritic Anterior Ischemic Optic Neuropathy"
      ],
      "interventions": [
        {
          "name": "RPh201 Cohort A",
          "type": "DRUG"
        },
        {
          "name": "Placebo Cohort A",
          "type": "OTHER"
        },
        {
          "name": "RPh201 Cohort B",
          "type": "DRUG"
        },
        {
          "name": "Placebo Cohort B",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Regenera Pharma Ltd",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 165,
      "start_date": "2018-07-10",
      "completion_date": "2020-09-27",
      "has_results": false,
      "last_update_posted_date": "2020-10-12",
      "last_synced_at": "2026-10-16T19:49:56.780Z",
      "location_count": 15,
      "location_summary": "Palo Alto, California • Pasadena, California • Orange, Connecticut + 12 more",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Pasadena",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "Connecticut"
        },
        {
          "city": "Waterbury",
          "state": "Connecticut"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03547206"
    },
    {
      "nct_id": "NCT06543446",
      "title": "Comparative Effectiveness of Prophylactic ICD Versus Non-ICD Therapy",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Heart Failure With Reduced Ejection Fraction"
      ],
      "interventions": [
        {
          "name": "ICD implantation",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "University of Rochester",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3290,
      "start_date": "2025-03-04",
      "completion_date": "2026-04-30",
      "has_results": false,
      "last_update_posted_date": "2026-05-12",
      "last_synced_at": "2026-10-16T19:49:56.780Z",
      "location_count": 13,
      "location_summary": "Portland, Maine • Baltimore, Maryland • Boston, Massachusetts + 10 more",
      "locations": [
        {
          "city": "Portland",
          "state": "Maine"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06543446"
    },
    {
      "nct_id": "NCT01177566",
      "title": "Pimecrolimus Cream 1% (Elidel®) and Medicated Device Cream (EletoneTM) in the Treatment and Maintenance of Atopic Dermatitis.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Atopic Dermatitis"
      ],
      "interventions": [
        {
          "name": "pimecrolimus",
          "type": "DRUG"
        },
        {
          "name": "topical medical device",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Emer, Jason, M.D.",
      "sponsor_class": "INDIV",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "2 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2009-09",
      "completion_date": "2010-03",
      "has_results": false,
      "last_update_posted_date": "2010-08-09",
      "last_synced_at": "2026-10-16T19:49:56.780Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01177566"
    }
  ]
}